Close Menu

NEW YORK – Gene editing company Inscripta announced on Tuesday that it has raised $125 million in a Series D financing round.

Paladin Capital Group led the round, with support from existing investors and new investors JS Capital Management and Oak HC/FT. The company said it has now raised $259.5 million — its Series C round raised a total of $105.5 million after two expansions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.